Nuran Katgi

Dr. Suat Seren Chest Diseases And Chest Surgery Training And Research Hospital, Izmir, 
Yenisehir, TR 
Dr. Suat Seren Chest Diseases And Chest Surgery Training And Research Hospital, Izmir, 
Yenisehir, TR 

Overview

Nuran Katgi practices practicing medicine in Yenisehir, Turkey.

Her clinical expertise encompasses EGFR Positive Lung Cancer, Lung Cancer, Sarcoidosis, and Non-Small Cell Lung Cancer (NSCLC).

She is actively involved in clinical research, co-authoring 16 peer reviewed articles and participating in 1 clinical trial.

Gender

Female

Locations

Dr. Suat Seren Chest Diseases And Chest Surgery Training And Research Hospital, Izmir, Yenisehir, Turkey
Other Locations
Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital
Izmir, Turkey
Ege, Turkey
Yenisehir, Turkey

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC)
A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: April 26, 2021
Intervention Type: Drug
Study Phase: Phase 3

16 Total Publications

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial.
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial.
Journal: JTO clinical and research reports
Published: October 21, 2025

Frequently Asked Questions about Nuran Katgi

Is Nuran Katgi a top-rated expert for EGFR Positive Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Nuran Katgi is classified as an Experienced expert for EGFR Positive Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Nuran Katgi participate in research or clinical trials?

Yes. Nuran Katgi has published 16 articles and abstracts on conditions like EGFR Positive Lung Cancer. You can view a list of Nuran Katgi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Katgi's expertise for a condition
ConditionClose
        View All 7 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile